The Drug Explorer

Search the nephrotoxic landscape

A live index of 240+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, and era. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.

6 agents · filtered from 240

Carmustine (BCNU)

BiCNU · Nitrosourea alkylator

Profile

Delayed interstitial fibrosis with high cumulative dose.

CINTMA
ModerateOpen →

Fotemustine

Muphoran · Nitrosourea (alkylating)

Profile

Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.

CINATNLYTE
ModerateOpen →

Lomustine (CCNU)

Gleostine · Nitrosourea alkylator

Profile

Cumulative interstitial nephritis and CKD.

CIN
ModerateOpen →

Lutetium-177 Dotatate

Lutathera · Radioligand therapy (PRRT)

Profile

Peptide receptor radionuclide therapy; proximal tubular radiation nephropathy is dose-limiting — amino-acid co-infusion is renoprotective.

CINTMA
ModerateOpen →

Lutetium-177 PSMA-617 (vipivotide)

Pluvicto · Radioligand therapy (PSMA)

Profile

PSMA-targeted radioligand for prostate cancer; renal radiation exposure and xerostomia.

CINLYTE
ModerateOpen →

Nimustine (ACNU)

Nidran · Nitrosourea (alkylating)

Profile

Water-soluble nitrosourea; renal risk inferred at class level; cumulative delayed tubulointerstitial injury; DLT is myelosuppression.

CINATNLYTE
ModerateOpen →